CHEMICALLY MODIFIED RECOMBINANT HUMAN SULFAMIDASE ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 2 |
19. ライソゾーム病
臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-002806-10-NL (EUCTR) | 29/11/2019 | 08/11/2018 | An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | Mucopolysaccharidosis Type IIIA or Sanfilippo Syndrome MedDRA version: 20.1;Level: LLT;Classification code 10028094;Term: Mucopolysaccharidosis IH;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Chemically modified recombinant human sulfamidase Product Code: SOBI003 INN or Proposed INN: not applicable Other descriptive name: CHEMICALLY MODIFIED RECOMBINANT HUMAN SULFAMIDASE | Swedish Orphan Biovitrum AB (publ) | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 1 | United States;Turkey;Germany;Netherlands | ||
| 2 | EUCTR2017-002806-10-DE (EUCTR) | 01/10/2018 | An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | Mucopolysaccharidosis Type IIIA or Sanfilippo Syndrome MedDRA version: 20.1;Level: LLT;Classification code 10028094;Term: Mucopolysaccharidosis IH;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Chemically modified recombinant human sulfamidase Product Code: SOBI003 Other descriptive name: CHEMICALLY MODIFIED RECOMBINANT HUMAN SULFAMIDASE | Swedish Orphan Biovitrum AB (publ) | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 1 | United States;Turkey;Netherlands;Germany |